Subcutaneous Keytruda
Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through
Merck, Legal patent, Subcutaneous Keytruda, Halozyme
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date